Conor Corio
This article was originally published in The Gray Sheet
Executive Summary
Firm announces initiation of the 150-patient RAPID trial to evaluate its Corio pimecrolius-eluting stent in Brazil and Europe on May 11. The drug - licensed from Novartis in March - prevents inflammation, which is believed to be a primary cause of restenosis, according to Conor Medsystems. Data from the study will be compared to historical controls from the firm's EuroSTAR study, which evaluated its CoStar paclitaxel-eluting stent. The trial also will evaluate a reduced duration of anti-platelet therapy following stent implantation. Conor expects to complete enrollment for the RAPID study in the second half of this year, with initial results available in 2007. The firm also plans to test a drug-eluting stent that combines pimecrolius and paclitaxel (1"The Gray Sheet" Feb. 20, 2006, p. 7)...